Emerson joins with Enterprise System Partners to accelerate product manufacturing pipelines
Technology and engineering company Emerson has selected Enterprise System Partners (ESP), a global consulting and project engineering company, to collaborate with and assist life sciences manufacturers in implementing the Syncade manufacturing execution system (MES) to improve operations management and accelerate product manufacturing pipelines for new biotech and pharmaceutical therapies.
Emerson’s Syncade MES combines document, equipment and materials management into electronic work procedures to create an optimised manufacturing environment for life sciences organisations. It is said to improve manufacturing operation, enabling the user to focus their energy on achieving operational goals.
By understanding the challenges of MES projects, Emerson and ESP have refreshed their execution model and methodology. Now the team deploys an iterative approach to project delivery that is said to enable life science enterprises to adopt new technology faster — and start up more rapidly. Faster, iterative approaches will help ensure projects reflect the project vision and end-user requirements, while helping Emerson and ESP meet increased demand for the Syncade MES.
“ESP’s business has been about best-in-class project delivery of MES solutions to the life science industry for the last 15 years,” said ESP Managing Director Liam O’Brien. “We are delighted to share that expertise with Emerson for the application of their world-class industry products.
“The synergy that exists between our two companies in understanding the complexities of MES projects provides our clients with innovative solutions to increase efficiency and avail of advanced work methodologies.”
“In selecting ESP to collaborate, we have set the stage for even more efficient project execution,” added Tom Snead, president of global life sciences industry for Emerson. “As life sciences manufacturers are pressured to bring medicines to patients sooner, we provide a path to keep pace with patient and market needs.”
A locally developed molecule called an 'i-body' serves as a powerful inhibitor of...
The MRCF has announced a $7 mllion investment in Cincera Therapeutics, a biotech company seeking...
Injecting mice with iPSCs launched a strong immune response against breast, lung and skin...